The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release.
The decision was supported by positive 1-year data from the phase 3 Pagoda study, in which Susvimo (ranibizumab injection, Genentech) 100 mg/mL refilled every 6 months yielded sustained vision improvements that were noninferior to vision improvements in those who received monthly intravitreal injections of 0.5 mg ranibizumab. In addition, safety was consistent with the known profile for Susvimo.
Susvimo continuously delivers ranibizumab through the port delivery platform and is the “first